Innovative Therapeutics Synklino is developing first-in-class therapies targeting CMV infections in transplant patients, creating opportunities to collaborate with organ transplant centers and hospitals seeking advanced infection management solutions.

Funding Momentum With recent Series A funding of EUR 29.8M and ongoing financing efforts, Synklino may be open to strategic partnerships or investments that support clinical expansion, manufacturing, and regulatory milestones.

Clinical Progress As Synklino approaches key clinical data milestones expected in 2026, there is an opportunity to engage with clinical institutions, healthcare providers, and pharma partners interested in novel transplant therapies.

Growing Expertise Led by experienced board members and medical personnel, Synklino is positioned as an innovative biotech firm, which could benefit from partnerships with specialized CROs, research institutions, and medical device companies.

Market Positioning Operating within the niche of viral infection treatments for transplantation with limited direct competitors, Synklino presents potential for early market entry collaborations with biotech and pharma organizations focused on transplant immunology.